These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28089229)

  • 1. Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?
    Mansfield AS
    Lung Cancer; 2017 Mar; 105():49-51. PubMed ID: 28089229
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel therapies for malignant pleural mesothelioma.
    Scherpereel A; Wallyn F; Albelda SM; Munck C
    Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.
    Tallón de Lara P; Cecconi V; Hiltbrunner S; Yagita H; Friess M; Bode B; Opitz I; Vrugt B; Weder W; Stolzmann P; Felley-Bosco E; Stahel RA; Tischler V; Britschgi C; Soldini D; van den Broek M; Curioni-Fontecedro A
    Clin Cancer Res; 2018 Dec; 24(24):6345-6354. PubMed ID: 30154226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant mesothelioma clinical trial combines immunotherapy drugs.
    Chatwal MS; Tanvetyanon T
    Immunotherapy; 2018 Apr; 10(5):341-344. PubMed ID: 29473471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
    Lee HS; Jang HJ; Choi JM; Zhang J; de Rosen VL; Wheeler TM; Lee JS; Tu T; Jindra PT; Kerman RH; Jung SY; Kheradmand F; Sugarbaker DJ; Burt BM
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions.
    Wong RM
    J Thorac Oncol; 2016 Oct; 11(10):1602-3. PubMed ID: 27663394
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
    Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blockade in malignant mesothelioma.
    Calabrò L; Maio M
    Semin Oncol; 2015 Jun; 42(3):418-22. PubMed ID: 25965359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
    Cheng M; Durm G; Hanna N; Einhorn LH; Kong FS
    Future Oncol; 2017 Dec; 13(28):2503-2505. PubMed ID: 29168656
    [No Abstract]   [Full Text] [Related]  

  • 12. Mesothelioma and small cell lung cancer.
    Tsao AS; Heymach J
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1825-6. PubMed ID: 22005546
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.
    Yamazoe M; Ozasa H; Kim YH
    J Thorac Oncol; 2019 Nov; 14(11):e251-e253. PubMed ID: 31668324
    [No Abstract]   [Full Text] [Related]  

  • 14. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
    Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
    Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
    Mohamed H; Eltobgy M; Abdel-Rahman O
    Anticancer Agents Med Chem; 2017; 17(9):1228-1233. PubMed ID: 28042777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
    Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
    J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant Mesothelioma: Time to Translate?
    Napolitano A; Carbone M
    Trends Cancer; 2016 Sep; 2(9):467-474. PubMed ID: 28603777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral lymphadenopathy as the initial manifestation of malignant mesothelioma in a child.
    Gong YS; Rong YT; Han WC; Zhang YC
    Hum Pathol; 2013 Apr; 44(4):664-9. PubMed ID: 23313308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.
    Hamaidia M; Gazon H; Hoyos C; Hoffmann GB; Louis R; Duysinx B; Willems L
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31534051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.